2026 Regular Session
SB435
Public Health - Medetomidine and Xylazine Consumer Protection Act
Prohibiting a retailer from distributing, selling, or exposing for sale a medetomidine product or xylazine product unless the purchaser provides proof the intended use is for institutional, veterinary, or scientific purposes; prohibiting a retailer from distributing, selling, or exposing for sale a medetomidine or xylazine product to an individual under the age of 21 years; requiring a retailer that prepares, distributes, sells, or exposes for sale a medetomidine or xylazine product to maintain certain records; etc.
Legislative progress
i
This summary includes only completed milestones supported by recorded actions. It does not predict the next step, and it preserves later committee reassignments, concurrence, conference, veto, and approval actions when they occur.
Committee referrals
January 30, 2026 · Senate
Finance
Instrument history
i
This is the complete recorded action history in the current source package. Highlighted entries are marked as significant by the source. A roll-call link appears only when a vote-like action has one unambiguous same-day chamber vote.
-
Senate Motion Laid Over (Senator Ready) Adopted
-
Senate Favorable with Amendments {983727/1
-
Senate Favorable with Amendments Report by Finance
-
Senate Hearing 2/11 at 2:00 p.m.
-
Senate First Reading Finance